Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ErbB receptor agonist in preparing medicines for treating ischemic cerebrovascular diseases

A receptor agonist, cerebrovascular disease technology, used in cardiovascular system diseases, drug combinations, pharmaceutical formulations, etc., can solve problems such as unreported and patented, and achieve good application prospects.

Inactive Publication Date: 2012-03-28
ZHEJIANG UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In ischemic cerebrovascular disease, there are no reports and patents on the protective drugs of the associated signal transduction pathway targeting ErbB under the pathological conditions of ischemic brain injury

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ErbB receptor agonist in preparing medicines for treating ischemic cerebrovascular diseases
  • Application of ErbB receptor agonist in preparing medicines for treating ischemic cerebrovascular diseases
  • Application of ErbB receptor agonist in preparing medicines for treating ischemic cerebrovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1: Protective effect of NRG1 on OGD-induced injury of cultured neuron cells

[0020] Drugs and reagents:

[0021] High-glucose DMEM and high-glucose DMEM medium were purchased from GIBICO Company in the United States, NRG1 was purchased from Prospec Company in the United States, and fetal bovine serum and neonatal calf serum were purchased from Hangzhou Sijiqing Bioengineering Materials Research Institute. ErbB4 rabbit anti-primary antibody (Santa Cruz Biotechnology), mouse secondary antibody (Amersham Bioscience), and other reagents are domestic and imported analytical reagents.

[0022] Cell culture:

[0023] Fetal mice were taken at 18 days of pregnancy, and the brain was quickly removed under aseptic conditions and placed in D.Hank's solution. The meninges and blood vessels were separated and peeled off under a dissecting microscope, and the cerebral cortex was separated. The cortical brain tissue was cut into pieces and placed in a centrifuge. Tube. Dige...

Embodiment 2

[0027] Example 2: Changes in subcellular distribution of ErbB4 under hypoxic and glucose-deficient conditions and NRG regulation Drugs and reagents:

[0028] High-glucose DMEM and high-glucose DMEM medium were purchased from GIBICO Company in the United States, NRG1 was purchased from Prospec Company in the United States, and fetal bovine serum and neonatal calf serum were purchased from Hangzhou Sijiqing Bioengineering Materials Research Institute. ErbB4 rabbit anti-primary antibody (Santa Cruz Biotechnology), rabbit secondary antibody (Amersham Bioscience), and other reagents are domestic and imported analytical reagents.

[0029] Cell culture:

[0030]Fetal mice were taken at 18 days of pregnancy, and the brain was quickly removed under aseptic conditions and placed in D.Hank's solution. The meninges and blood vessels were separated and peeled off under a dissecting microscope, and the cerebral cortex was separated. The cortical brain tissue was cut into pieces and placed i...

Embodiment 3

[0035] Example 3: NRG1-ErbB4 signaling pathway participates in the pathological process of ischemic brain injury Operation method:

[0036] Preparation of mouse middle cerebral artery transient ischemia-reperfusion model:

[0037] Male C57 mice, weighing 22-27 g. Mice were anesthetized with isoflurane gas, fixed, and the median neck was cut, and the left common carotid artery, internal carotid artery, and external carotid artery were separated. Ligate the proximal ends of the external carotid artery and the common carotid artery, cut the incision before the bifurcation of the internal carotid artery and the external carotid artery, and insert a 5-0 nylon suture with uniform diameter (causing cerebral ischemia). After 1.5 hours, the nylon suture Withdrawal (causing cerebral blood reperfusion phenomenon), the skin is sutured.

[0038] The experimental groups were as follows: sham operation group, cerebrovascular injury model group, and cerebrovascular injury+NRG1 treatment gro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of an ErbB receptor agonist in preparing medicines for treating ischemic cerebrovascular diseases By using neuronal injury models in vivo and in vitro as a research platform, the protection function of NRG1 to neuronal cell injuries and experimental cerebral ischemia are discovered, simultaneously the possible molecular mechanism of NRG1 is fully researched, and the cerebral protection effect by regulating and controlling NRG1-ErbB4 associated signal pathway after ischemic cerebral ischemia is fully argued, thus the study of NRG1 and associated ErbB4 agonist open up wide prospects for developing novel medicines for protecting cerebral neurocyte and controlling ischemic cerebrovascular diseases.

Description

(1) Technical field [0001] The invention relates to the application of ErbB receptor agonist in the preparation of medicine for treating ischemic cerebrovascular disease. (2) Background technology [0002] Cerebrovascular disease is the third leading cause of death in our country, of which ischemic stroke accounts for about 75%, and its morbidity and mortality are constantly rising. It is a major disease that seriously affects the health of our people and the national economy. The incidence of cerebrovascular disease is positively correlated with age, which increases with the aging of my country's population. Its incidence is on the rise. Taking stroke as an example, the annual incidence rate in my country is 150 / 100,000 people, the mortality rate is 120 / 100,000 people, about 75% of the survivors are disabled, and the 5-year recurrence rate is as high as 41%. The burden is increasing day by day. [0003] According to the statistics of the World Health Organization, the mor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K38/18A61P9/10
Inventor 李晓明卢应梅
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com